Explore All 557 Venture Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | November 30, 2017 |
| Target | Semma Therapeutics |
| Sector | Life Science |
| Investor(s) | Eight Roads |
| Deal Type | Venture |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1969 |
| PE ASSETS | 11.0B USD |
| Size | Mega |
| Type | Sector Focused |
Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.
| Deal Context for Investor | # |
|---|---|
| Overall | 169 of 293 |
| Sector: Life Science | 47 of 73 |
| Type: Venture | 148 of 266 |
| State: Massachusetts | 27 of 33 |
| Country: United States | 78 of 119 |
| Year: 2017 | 34 of 38 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-11-08 |
Apellis Pharmaceuticals
Waltham, Massachusetts, United States Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company, focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Uncontrolled complement activation can lead to a wide range of life-threatening or debilitating disorders. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-12-08 |
Denali Therapeutics
South San Francisco, California, United States Denali Therapeutics is a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. Denali Therapeutics was founded in 2013 and is based in South San Francisco, California. |
Sell | - |
